state Maryland covid-19 vaccine Coronavirus state Maryland

Novavax COVID vaccine 90% effective in phase 3 trial

Reading now: 147
www.cidrap.umn.edu

Novavax's two-dose COVID-19 vaccine showed 90% overall vaccine efficacy (VE), 100% protection against moderate and severe illness, and 93% VE against variants of concern and of interest in a phase 3 US clinical trial in adults, according to a company news release today.Maryland-based Novavax plans to file for regulatory authorization for adults within the next few months, the release said.

While authorization wouldn't likely have much effect on the already robust US vaccine supply, it could provide a badly needed boost to the international vaccine rollout.

Another plus is that it doesn't require ultra-cold temperatures for shipping and storage.The Coalition for Epidemic Preparedness Innovations (CEPI), a global group of government and

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA